Portal de Periódicos da CAPES

Spike Gene Target Amplification in a Diagnostic Assay as a Marker for Public Health Monitoring of Emerging SARS-CoV-2 Variants — United States, November 2021–January 2023

2023; Centers for Disease Control and Prevention; Volume: 72; Issue: 5 Linguagem: Inglês

10.15585/mmwr.mm7205e2

1545-861X

Heather M. Scobie, Akilah R. Ali, Philip Shirk, Zachary Smith, Prabasaj Paul, Clinton R. Paden, Norman Hassell, Xiaoyu Zheng, Anastasia S. Lambrou, Rebecca Kondor, Duncan MacCannell, Natalie J. Thornburg, Joseph D. Miller, Dave Wentworth, Benjamin J. Silk,

Viral gastroenteritis research and epidemiology

Monitoring emerging SARS-CoV-2 lineages and their epidemiologic characteristics helps to inform public health decisions regarding vaccine policy, the use of therapeutics, and health care capacity. When the SARS-CoV-2 Alpha variant emerged in late 2020, a spike gene (S-gene) deletion (Δ69-70) in the N-terminal region, which might compensate for immune escape mutations that impair infectivity (1), resulted in reduced or failed S-gene target amplification in certain multitarget reverse transcription-polymerase chain reaction (RT-PCR) assays, a pattern referred to as S-gene target failure (SGTF) (2). The predominant U.S. SARS-CoV-2 lineages have generally alternated between SGTF and S-gene target presence (SGTP), which alongside genomic sequencing, has facilitated early monitoring of emerging variants. During a period when Omicron BA.5-related sublineages (which exhibit SGTF) predominated, an XBB.1.5 sublineage with SGTP has rapidly expanded in the northeastern United States and other regions.